In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Cangrelor is a potent intravenous P2Y12 receptor inhibitor with rapid onset and offset of
action associated with a greater reduction in ischemic events, including stent thrombosis, in
patients undergoing stent procedures who have not been pretreated with clopidogrel. In vitro
investigations have shown cangrelor to be associated with more rapid, potent, and consistent
platelet inhibition in patients on maintenance prasugrel therapy exposed to a re-loading dose
of prasugrel. However, if cangrelor exerts similar effects in ticagrelor treated patients
remain unknown. The aim of the present study is to evaluate the effects on platelet function
achieved after in vitro incubation with cangrelor in patients on ticagrelor maintenance dose
who receive a loading dose of ticagrelor.